The majority of AML cases with post-chemotherapy lower TNF-a levels had complete remission (95.2%), while the majority of cases with post-chemotherapy higher TNF-a levels had incomplete remission (81.8%). The gene discussed is TNF; the disease is acute myeloid leukemia.